We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
High eradication rates of Helicobacter pylori with a new sequential treatment.
- Authors
Zullo, A.; Vaira, D.; Vakil, N.; Hassan, C.; Gatta, L.; Ricci, C.; De Francesco, V.; Menegatti, M.; Tampieri, A.; Perna, F.; Rinaldi, V.; Perri, F.; Papadìa, C.; Fornari, F.; Pilati, S.; Mete, L. S.; Merla, A.; Potì, R.; Marinone, G.; Savioli, A.
- Abstract
Summary Background : Eradication rates of Helicobacter pylori with standard triple therapy are disappointing, and studies from several countries confirm this poor performance. Aim : To assess the eradication rate of a new sequential treatment regimen compared with conventional triple therapy for the eradication of H. pylori infection. Methods : One thousand and forty-nine dyspeptic patients were studied prospectively. H. pylori -infected patients were randomized to receive 10-day sequential therapy [rabeprazole (40 mg daily) plus amoxicillin (1 g twice daily) for the first 5 days, followed by rabeprazole (20 mg), clarithromycin (500 mg) and tinidazole (500 mg) twice daily for the remaining 5 days] or standard 7-day treatment [rabeprazole (20 mg), clarithromycin (500 mg) and amoxicillin (1 g) twice daily]. H. pylori status was assessed by histology, rapid urease test and 13 C-urea breath test at baseline and 6 weeks or more after completion of treatment. Results : Higher eradication rates were found with the sequential regimen compared to the standard regimen (intention-to-treat: 92% vs. 74%, P < 0.0001; per protocol: 95% vs. 77%, P < 0.0001). Higher eradication rates were also seen in patients with peptic ulcer disease and non-ulcer dyspepsia. In both treatments, compliance was similar (> 90%), as was the rate of side-effects, which were mild. Conclusions : This 10-day sequential treatment regimen achieves high eradication rates in peptic ulcer disease and non-ulcer dyspepsia.
- Subjects
HELICOBACTER disease treatment; AMOXICILLIN; THERAPEUTICS
- Publication
Alimentary Pharmacology & Therapeutics, 2003, Vol 17, Issue 5, p719
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1046/j.1365-2036.2003.01461.x